Research at Oslo University Hospital

 

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic rsearch, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

 

Latest news

42 scientists from Oslo University Hospital granted 69.2 mill NOK from the Norwegian Cancer Society

 

Oslo University Hospital (OUH) celebrated on Tuesday October 28th this year's research funding from the Norwegian Cancer Society (NCS). Talks were held by cured ex-lymphoma patient Ulf Prytz and scientist Hege Russnes. OUH general director Bjørn Erikstein and head of the Divison of Cancer Medicine, Surgery and Transplantation Sigmund Smeland thanked the NCS on behalf of the hospital.
The projects granted support were announced by secretary-general in NCS Anne Lise Ryel. OUH received in total 69,2 mill NOK, distributed between 42 scientists.
Photos from the event will be published as soon as they are available.

 
 

The Inven2 Idea Prize 2014 distributed

 
From left: Inderberg Suso, Gaudernack and Wälchli
From left: Inderberg Suso, Gaudernack and Wälchli

The Inven2 idea prize 2014 was recently awarded to researchers from the Department for Cellular Therapy (Immunominotoring unit/molecular biology service) and Immunology (Lymphoma group).
Sébastien Wälchli (KKT and IKF, Molecular biology service), Else Marit Inderberg Suso (KKT, head of immunomonitoring unit), Gustav Gaudernack (IKF, former Head of Immunology Dept.) and Gunnar Kvalheim (KKT, Head of Dept. of Cellular Therapy) and have submitted a method to produce Universal killer cells for cancer cell therapy. The innovation relies on the use of the same therapeutic cells for all patients. This promising technology will reduce the cost and the time of preparation in adoptive cell transfer.

 
 

Vessela N. Kristensen's research group presented by the Norwegian Cancer Society

 
Post doc Thomas Fleischer and professor Vessela N. Kristensen
Post doc Thomas Fleischer and professor Vessela N. Kristensen

The Norwegian Cancer Society (NCS) provides approximately 25 per cent of all direct funding for cancer research in Norway, thus contributing to promoting a research environment of top international standard in the country. The research section of the NCS writes popular scientific articles about scientists supported by the society.
In October - the month of the pink ribbon breast cancer awareness campaign - the NCS have published an article about professor Vessela N. Kristensen from the Department of Genetics at the Institute for Cancer Research. Kristensen's "Cancer Genome Variation" group is working on projects related to how genetic variation affects occurrence of somatic alterations, gene expression patterns and genome wide copy number alterations in human breast and ovarian tumors.

 
 

Important findings from Department of Genetics published in Genome Biology and highlighted in Biome magazine

 
Inga H. Rye and Thomas Fleischer
Inga H. Rye and Thomas Fleischer

Scientists from Department of Genetics contribute to the special issue of Genome Biology (journal IF 10,5) dedicated to cancer heterogeneity and progression.
Inga H. Rye supervised by Hege Russnes developed with a group in Cambridge a software for automatized analyses of fluorescence, FISH and IFISH images to estimate both copy number variation and phenotypic traits. The software, GoIFISH, can also recognize different types of cells and visualize intra-tumor heterogeneity.
Thomas Fleischer, supervised by Vessela Kristensen from the group of Cancer Genome variation discovered an epigenetic signature of breast cancer progression with prognostic significance. This work was highlighted in the Biome magazine, which showcases some of the most interesting research publications from across BMC journals.

 
 

Research blog launched at Oslo University Hospital

 
Erlend B. Smeland
Erlend B. Smeland

The recently launched Oslo University Hospital research blog is the first site of this kind among Norwegian health care institutions. In the first contribution - entitled "Health research in great request" director of research, innovation and education Erlend B. Smeland writes about how the blog will act as a platform for communicating discoveries in medical sciences in a popularised form, as well as serving as a vehicle for the hospital to stay in touch with the community. It will also be used as a channel for voicing the views of the hospital in debates concerning research policies.

New contributions will appear on the blog every other week. At first, the heads of research at the various divisions will write in turn. Ingrid Melle from the Division of Mental Health and Addiction has kicked it off by writing about how mental illnesses may harm the body. The blog is in Norwegian.

 
 

Official opening of the KG Jebsen Colorectal Cancer Research Centre

 
Hans Peter Jebsen and Ragnhild A. Lothe
Hans Peter Jebsen and Ragnhild A. Lothe

The K.G. Jebsen Colorectal Cancer Research Centre was recently officially opened by the chair of the Jebsen Foundation’s board of directors, Hans Peter Jebsen. Prof. Ragnhild A. Lothe will lead the Centre together with the interdisciplinary PI team consisting of Prof. Michael Bretthauer (gastroenterologist), Prof. Arild Nesbakken (surgeon), Prof. Kjell Tveit (oncologist) and ass. Prof. Rolf I. Skotheim (bioinformatician).

This is the only Jebsen Centre in Oslo that has Oslo University Hospital as its main host institution. Prof. Sigbjørn Smeland, head of the hosting Division of Cancer, Surgery and Transplantation, said in his talk that the Centre was an excellent example of how to organise and succeed in translational research within a Comprehensive Cancer Centre.